Abstract
High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina
Radiation oncology (London, England), v 3(1), pp 7-7
13 Feb 2008
PMID: 18271958
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The purpose of this study was to evaluate the efficacy of HDR brachytherapy for primary or recurrent vaginal cancer.
Between the years 2000 to 2006, 18 patients with primary or recurrent vaginal cancer were treated with brachytherapy (HDRB). Six patients had primary vaginal cancer (stage II to IVA) while 12 were treated for isolated vaginal recurrence (primary cervix = 4, vulva = 1 and endometrium = 7). Five patients had previous pelvic radiation therapy. All except one patient received external beam radiation therapy to a median dose of 45 Gy (range 31.2-55.8 Gy). The HDRB was intracavitary using a vaginal cylinder in 5 patients and interstitial using a modified Syed-Nesblett template in 13 patients. The dose of interstitial brachytherapy was 18.75 Gy in 5 fractions delivered twice daily. The median follow-up was 18 months (range 6-66 months).
Complete response (CR) was achieved in all but one patient (94%). Of these 17 patients achieving a CR, 1 had local recurrence and 3 had systemic recurrence at a median time of 6 months (range 6-22 months). The 2-year actuarial local control and cause-specific survival for the entire group were 88% and 82.5%, respectively. In subset analysis, the crude local control was 100% for primary vaginal cancer, 100% for the group with recurrence without any prior radiation and 67% for group with recurrence and prior radiation therapy. Two patients had late grade 3 or higher morbidity (rectovaginal fistula in one patient and chronic vaginal ulcer resulting in bleeding in one patient). Both these patients had prior radiation therapy.
Our small series suggests that HDRB is efficacious for primary or recurrent vaginal cancer. Patients treated with primary disease and those with recurrent disease without prior irradiation have the greatest benefit from HDRB in this setting. The salvage rate for patients with prior radiation therapy is lower with a higher risk of significant complications. Additional patients and follow-up are ongoing to determine the long-term efficacy of this approach.
Metrics
Details
- Title
- High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina
- Creators
- Sushil Beriwal - UPMC Hillman Cancer CenterDwight E Heron - UPMC Hillman Cancer CenterRobert Mogus - UPMC Hillman Cancer CenterRobert P Edwards - Magee-Womens HospitalJoseph L Kelley - Magee-Womens HospitalPaniti Sukumvanich - University of Pittsburgh Medical Center
- Publication Details
- Radiation oncology (London, England), v 3(1), pp 7-7
- Publisher
- Springer BMC
- Resource Type
- Abstract
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000260414000001
- Scopus ID
- 2-s2.0-41149160694
- Other Identifier
- 991021897285104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging